ADAM10 and neoplasm: DPAGT1-overexpressing SK-BR-3 tumors with ADAM10 KO showed a sensitive response to trastuzumab treatment, as indicated by significant shrinkage of tumor volumes (Figure 7E and Supplemental Figure 7C).